← SynDRA
PACRITINIB
SynDRA canonical compound SYN0029224 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
| Approval status | Approved · Rx |
| Primary target(s) | CDK2 | FLT3 | JAK1 | JAK2 | JAK3 |
| Mechanism of action | FLT3 inhibitor | JAK inhibitor |
All known targets
- FLT3
- JAK2
- ACVR1
- JAK3
- IRAK1
- JAK1
- AAK1
- PDGFRB
- MAP4K2
- MAP4K4
- MAPK8
- NEK9
Mechanisms of action (all sources)
- JAK2 INHIBITOR
- Tyrosine-protein kinase JAK2 inhibitor
- FLT3 INHIBITOR
- Tyrosine-protein kinase receptor FLT3 inhibitor
- ACVR1 INHIBITOR
- Activin receptor type-1 inhibitor
- IRAK1 INHIBITOR
- Interleukin-1 receptor-associated kinase 1 inhibitor
- JAK inhibitor
- FLT3 MODULATOR
- JAK3 MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ABL1
- ABL2
- NLK
- NTRK1
- NUAK2
- OLA1
- OPA1
- PAICS
- PAK4
- PASK
- PDXK
- PEBP1
- PFKP
- PHKG2
- PIM1
- PIP4K2C
- PKMYT1
- PKN1
- PKN2
- PLK4
- PRKAA1
- PRKACA
- PRKACB
- PRKACG
- PRKAG1
- PRKAG2
- PRKAR2A
- NEK3
- NEK2
- NEK1
- MARK3
- MAP4K5
- MAPK1
- MAPK10
- MAPK11
- MAPK14
- MAPK15
- MAPK3
- MAPK9
- MAPKAPK2
Drug classes
- Tyrosine Kinase Inhibitors
- Kinase Inhibitor
- Cytochrome P450 1A2 Inhibitors
- Cytochrome P450 3A4 Inhibitors
- P-Glycoprotein Inhibitors
- Breast Cancer Resistance Protein Inhibitors
- Janus Kinase Inhibitors
- Organic Cation Transporter 1 Inhibitors
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- VONJO
- Vonjo
- pacritinib citrate
- vonjo
- SB1518
- SB-1518
- ONX-0803
- JAK inhibitor (alone or in combination)s
- Pacritinib (SB1518)
- SB 1518
- Pacritinib(SB1518)
- ONX 0803
- G22N65IL3O
- CHEMBL2181330
- Pacritinib [INN]
- Pacritinib (USAN/INN)
- Pacritinib [USAN:INN]
- PACRITINIB [USAN]
- PACRITINIB [WHO-DD]
- SB-1518 TFA salt
- UNII-G22N65IL3O
- GTPL7793
- SCHEMBL1108221
- CHEMBL2035187
- SCHEMBL22819303
- EX-A240
- DTXSID801045679
- AMY23364
- BAX 2201
- BCP09091
- BDBM50210177
- BDBM50400312
- MFCD22572772
- NSC759674
- NSC781626
- s8057
- AKOS037515687
- CCG-269464
Look up PACRITINIB in the interactive SynDRA portal →